Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives.

about

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives.

Item

http://www.wikidata.org/entity/Q47097042

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Octreotide long-acting repeata ...... nt selection and perspectives.

@en

Octreotide long-acting repeata ...... nt selection and perspectives.

@nl

type

Item

label

Octreotide long-acting repeata ...... nt selection and perspectives.

@en

Octreotide long-acting repeata ...... nt selection and perspectives.

@nl

prefLabel

Octreotide long-acting repeata ...... nt selection and perspectives.

@en

Octreotide long-acting repeata ...... nt selection and perspectives.

@nl

P1476

Octreotide long-acting repeata ...... nt selection and perspectives.

@en

P2093

Andreas G Moraitis

http://www.w3.org/2001/XMLSchema#string

Mustafa Kinaan

http://www.w3.org/2001/XMLSchema#string

Suzanne L Quinn

http://www.w3.org/2001/XMLSchema#string

P2860

Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data.

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.

Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience.

Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion.

68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.

Antitumor effects of somatostatin analogs in neuroendocrine tumors.

P304

115-122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/BTT.S108818

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hanford Yau

P577

2017-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29255345

http://www.w3.org/2001/XMLSchema#string

P932

5723116

http://www.w3.org/2001/XMLSchema#string